An Open-Label, Multicenter, Randomized, Phase 2 study of a recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-Line Treatment of Patients with Recurrent or Advanced Non-Small Cell lung cancer (NSCLC).

Objective

This is a clinical trial of the study drug IMC-1121 B that will be administered by IV, which is investigational, and platinum based chemotherapy that includes pemetrexed, carboplatin and cisplatin that are administered by IV, which is standard of care.

IRB Protocol Number

10-0797

Principal Investigator(s)

ROBERT DOEBELE

Cancer Trials

• Lung Cancer

Sponsor(s)

ImClone Systems, Inc.

Contact

AMY BROWN at 720-848-0603
or AMY.M.BROWN@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last up to 18 weeks, and a possible maintenance period that requires a clinic visit every three weeks. // Eligibility criteria include but are not limited to 18 years or older with recurrent or advanced non-small cell lung cancer.